AngioDynamics Sets Sights on Prostate Cancer with New IDE

FDA has given approval for AngioDynamics to undergo a pilot study of the NanoKnife for the ablation of prostate cancer tissue in low-risk patients. The IDE comes on the heels of the Latham, NY-based company making significant strides in its mission to obtain an indication for the treatment of pancreatic cancer. “NanoKnife has been in the market for a general soft tissue claim for about eight or nine years,” Brent Boucher, AngioDynamics, Senior VP and General Manager of Oncology, told MD+DI. “On April 1 we received approval to pursue a pancreas indication for stage three pancreatic cancer. We enrolled our first patient about three weeks ago There will be a total of six patients at three sites in the U.S. for the prostate pilot study. Boucher noted that the pilot study for prostate would give AngioDynamics the ability to engage in dialogue with FDA about what the pivotal study would be. If the company can get approval, the NanoKnife could have tremendous implications for prostate cancer. AngioDynamics said as it stands now, prostate cancer is the second leading cause of cancer death in American men. Approximately one man out of every nine will be diagnosed with prostate cancer during his lifetime. Traditional treatment options have focused on standard whole-gland therapies, such as active surveillance, radical prostatectomy, and external beam radiation. However, over the last decade, focal therapy has been evaluated as an al...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news

Related Links:

Publication date: Available online 2 April 2020Source: Urology Case ReportsAuthor(s): Takashi Ando, Kazuhiro Watanabe, Takaki Mizusawa, Takeshi Sakai, Akiyoshi Katagiri
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Conditions:   Breast Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Metastatic Prostate Cancer Interventions:   Behavioral: In Person Counseling;   Behavioral: Educational Video Sponsors:   Dana-Farber Cancer Institute;   Ambry Genetics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Background: Dipeptidyl peptidase-4 (DPP4), a cell surface protein, exhibits a crucial role in tumor biology and regulation of the immune system. We aim to study the impact of DPP4 inhibitors (DPP4i) in patients with prostate cancer (PRC), pancreatic cancer (PC) and breast cancer (BC).Methods: Using the SEER and Medicare linked database, we identified patients with PRC or PC or BC with coexisting type II diabetes mellitus between 2007 and 2015. Patients were classified into four groups: (1) not on either DPP4i or metformin (reference group), this group included patient that were on anti-diabetic agents other than metformin ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
e;n Z Abstract Germinal or somatic mutations of the BRCA genes may serve as therapeutic targets. Deficient functioning of the BRCA genes render the cancer vulnerable to such therapeutic interventions as chemotherapy with DNA-targeted agents and PARP inhibitors targeting DNA repair capacity. Although BRCA mutations may be detected in a large variety of cancers, the mentioned specific therapies are efficient in the so called BRCA-associated cancers only including ovarian, breast, pancreatic, prostate cancers and the rare uterine sarcomas. While in ovarian and prostate carcinomas both germinal and somatic, in breast ...
Source: Magyar Onkologia - Category: Cancer & Oncology Authors: Tags: Magy Onkol Source Type: research
ConclusionBased on the vesicular cargo, the molecular constituents, the exosomes have the potential to change the fate of macrophage phenotypes, either M1, classically activated macrophages, or M2, alternatively activated macrophages. In this review, we discuss and describe the ability of tumor-derived exosomes in the mechanism of macrophage activation and polarization.
Source: Inflammation Research - Category: Research Source Type: research
We present a 60-year-old man with known prostate cancer treated with robot-assisted radical prostatectomy. Prostate-specific antigen levels did not decline accordingly, and a second Ga-PSMA PET/CT demonstrated a new focus with high Ga-PSMA uptake in the pancreatic tail. A subsequent CT scan did not display the lesion as a typical pancreatic tumor, and a spleen scintigraphy was also negative excluding an ectopic intrapancreatic accessory spleen. Ga-DOTATOC PET/CT showed uptake in the same area of the pancreatic tail consistent with a neuroendocrine tumor. This case illustrates that neuroendocrine tumors can be important pit...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Nucl Med Source Type: research
(CG Life) Bluestar Genomics published a new study demonstrating the efficacy of their 5-hydroxymethylcytosine (5hmC) signal detection technology for its use in breast, lung, pancreatic, and prostate cancer.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Authors: Kind S, Merenkow C, Büscheck F, Möller K, Dum D, Chirico V, Luebke AM, Höflmayer D, Hinsch A, Jacobsen F, Göbel C, Weidemann S, Fraune C, Möller-Koop C, Hube-Magg C, Clauditz TS, Simon R, Sauter G, Wilczak W, Bawahab AA, Izbicki JR, Perez D, Marx A Abstract Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various normal and malignant tissues. It is of interest because of a possible prognostic role of differential expression in tumors and its role as a target for indatuximab, a monoclonal antibody coupled with a cytotoxic agent. To comprehensively analyze ...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Publication date: Available online 3 January 2020Source: Seminars in Cancer BiologyAuthor(s): Kelly Olino, Tristen Park, Ntia AhujaAbstractAdvances in immunotherapy, most notably antibodies targeting the inhibitory immune receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4/CD152), programmed death protein 1 (PD-1/CD279) and programmed death-ligand 1 (PD-L1/B7H1/CD274) have become effective standard therapies in advanced malignancies including melanoma,1–4 merkel cell carcinoma5, urological cancers6–8, non-small cell lung cancer9–11, mis-match repair (MMR) deficient tumors12, and Hodgkin lymphoma...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This study investigated the types treated at the institutions in rural communities of Japan. A questionnaire survey was conducted for 811 public rural institutions (clinics and small-to-middle-sized hospitals [
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
More News: Cancer | Cancer & Oncology | External Beam Therapy | Medical Devices | Nanotechnology | Pancreas | Pancreatic Cancer | Prostate Cancer | Prostatectomy | Study | Toxicology